Vaxcyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	129.78	129.37	92.9	60.7	39.81	25.26
Research & Development	958.95	794.31	476.64	332.34	169.45	78.41
Other Operating Expenses	-	-	-	75	23	-
Total Operating Expenses	1,089	923.68	569.55	468.04	232.26	103.67
Operating Income	-1,089	-923.68	-569.55	-468.04	-232.26	-103.67
Interest Income	113.39	119.72	109.99	62.91	8.36	0.34
Interest Expense	-	-	-	-	-0	-0.01
Other Non-Operating Income (Expense)	28.81	37.33	-4.38	2.87	0.42	3.26
Total Non-Operating Income (Expense)	142.2	157.05	105.62	65.78	8.77	3.59
Pretax Income	-946.53	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income	-946.53	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income to Common	-946.53	-766.63	-463.93	-402.27	-223.49	-100.08
Shares Outstanding (Basic)	137	136	122	97	65	52
Shares Outstanding (Diluted)	137	136	122	97	65	52
Shares Change (YoY)	7.10%	11.55%	25.57%	49.75%	24.95%	75.73%
EPS (Basic)	-6.88	-5.63	-3.80	-4.14	-3.44	-1.93
EPS (Diluted)	-6.88	-5.63	-3.80	-4.14	-3.44	-1.93
Free Cash Flow	-814.94	-712.55	-571.79	-364.67	-176.44	-127.95
Free Cash Flow Per Share	-5.95	-5.24	-4.69	-3.75	-2.72	-2.46
EBITDA	-1,063	-898.82	-553.7	-457.87	-222.8	-100.21
EBIT	-1,089	-923.68	-569.55	-468.04	-232.26	-103.67

SEC Filings: 10-K · 10-Q